SCHEMBL270374

SCHEMBL270374

[C-]#[N+]c1cnc(Nc2cccc(OCCN3CCCC3)c2)nc1N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 5/20 0.51
YES1 P07947 2/20 0.51
SYK P43405 4/20 0.50
EGFR P00533 4/20 0.48
BTK Q06187 2/20 0.48
BRD4 O60885 3/20 0.47
AIMP2 Q13155 1/20 0.47
CHRNB2 P17787 1/20 0.46
CHRNA4 P43681 1/20 0.46
JAK2 O60674 3/20 0.46
JAK3 P52333 3/20 0.46
BRDT Q58F21 2/20 0.46
BRD2 P25440 1/20 0.46
BRD3 Q15059 1/20 0.46
ITK Q08881 3/20 0.45
JAK1 P23458 2/20 0.44
AXL P30530 2/20 0.44
PDGFRB P09619 2/20 0.44
BRAF P15056 2/20 0.44
BMPR1B O00238 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL270390 0.88 BACE1 (0.56) BRD4JAK2JAK3JAK1AXL
SCHEMBL263867 0.82 PRKCQ (0.51) SRCYES1SYKEGFRBTK
SCHEMBL12190209 0.82 SRC (0.56) SRCYES1SYKEGFRBTK
SCHEMBL19462075 0.80 SRC (0.54) SRCYES1SYKEGFRBTK
SCHEMBL12278053 0.79 SYK (0.52) SRCYES1SYKEGFRBTK
SCHEMBL3458766 0.79 AIMP2 (0.58) SRCYES1EGFRBRD4AIMP2
SCHEMBL269990 0.78 SYK (0.48) SRCYES1SYKEGFRBTK
SCHEMBL4880015 0.77 AIMP2 (0.57) SRCYES1AIMP2CHRNB2CHRNA4
SCHEMBL4870283 0.75 SRC (0.51) SRCYES1SYKEGFRBTK
SCHEMBL3459161 0.75 SRC (0.57) SRCSYKEGFRBTKAIMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138199-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-20 US disclosed
US-8133900-B2 Use of bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2012-03-13 US disclosed
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-09-01 US disclosed
US-7825246-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2010-11-02 US disclosed
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases TARGEGEN, INC. (US) 2009-11-19 US disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, LTK SRC 73/4885YES1 642/4885SYK 59/4885
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 SRC 80/4885YES1 386/4885SYK 281/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 SRC 80/4885YES1 386/4885SYK 281/4885
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 SRC 80/4885YES1 386/4885SYK 281/4885
US-20110212077-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES JAK2, TYK2, JAK3 SRC 80/4885YES1 386/4885SYK 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.